SeqLL Inc. Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Initial Public Offering
30 Settembre 2021 - 12:04AM
SeqLL Inc. (“SeqLL” or the “Company”)
(NASDAQ:SQL; SQLLW), a development-stage life
sciences instrumentation and research services company engaged in
the development of scientific assets and novel intellectual
property across multiple “omics” fields, today announced the
closing of the sale of an additional 189,000 shares of common stock
at the initial public offering price of $4.24 per share, pursuant
to the partial exercise of the underwriters’ over-allotment option,
in connection with its initial public offering that closed on
August 31, 2021, resulting in gross proceeds of approximately
$801,360. After giving effect to the exercise of the over-allotment
option, the total gross proceeds of the initial public offering
increased to approximately $13,810,950.
Maxim Group LLC acted as the sole book-running
manager in connection with the offering.
A registration statement on Form S-1 (File Nos.
333-254886 and 333-259097) was filed with the Securities and
Exchange Commission (“SEC”), which became effective on August 26,
2021. A final prospectus relating to the offering was filed
with the SEC and is available on the SEC's website at
http://www.sec.gov. The offering was made only by means of a
prospectus forming part of the effective registration statement.
Electronic copies of the prospectus relating to this offering may
be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New
York, New York 10022, at (212) 895-3745. Before investing in the
Company’s securities, interested parties should read in its
entirety the registration statement that the Company has filed with
the SEC, which provides additional information about the Company
and this offering.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About SeqLL:SeqLL Inc.
(“SeqLL”) is a development-stage life sciences instrumentation and
research services company engaged in the development of scientific
assets and novel intellectual property across multiple “omics”
fields. The Company intends to leverage their expertise with True
Single Molecule Sequencing (“tSMS®”) technology to enable
researchers and clinicians to contribute major advancements to
scientific research and development by accelerating one’s
understanding of the molecular mechanisms of disease and
fundamental biological processes.
Forward Looking Statements:
This press release contains certain
forward-looking statements, including those relating to the
regarding the use of proceeds and other statements that are
predictive in nature. Forward-looking statements are based on the
Company's current expectations and assumptions. The Private
Securities Litigation Reform Act of 1995 provides a safe-harbor for
forward-looking statements. These statements may be identified by
the use of forward-looking expressions, including, but not limited
to, "expect," "anticipate," "intend," "plan," "believe,"
"estimate," "potential," "predict," "project," "should," "would"
and similar expressions and the negatives of those terms.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this presentation. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events or otherwise. Important factors that
could cause actual results to differ materially from those in the
forward-looking statements are set forth in the Company's filings
with the Securities and Exchange Commission, including its
registration statement on Form S-1, as amended from time to time,
under the caption "Risk Factors."
Contact:John
Kennedyinvestors@seqll.com
Grafico Azioni SeqLL (NASDAQ:SQL)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni SeqLL (NASDAQ:SQL)
Storico
Da Giu 2023 a Giu 2024